Hawthorne Effect: $20m Series A financing
Decentralized trial solutions firm Hawthorne Effect announced it has closed a $20m USD Series A funding round. The investment funds reportedly will be used accelerate growth and fuel the company’s mission to help alleviate key issues related to patient recruitment and retention.
“We figured out that clinical trial continuity has the same root cause as equity gaps in health care delivery — accessibility and convenience for patients,” said Jodi Akin, Hawthorne Effect CEO and founder. “While there is great momentum in the adoption of decentralized clinical trials, apps just don’t draw blood, nor do they reach the equity divide; Hawthorne Effect uniquely offers the only technology-enabled distributed professionals model that addresses these common barriers in clinical research.”
